Ovarian Cancer News

CancerConnect ovarian cancer news, tips, and features provide breaking research stories, helpful tips, and inspiring features related to ovarian cancer. The unique daily cancer news service evaluates all aspects of ovarian cancer research and reports on the developments that are most important to cancer patients and healthcare providers, while the tips and features offer insight into all aspects of ovarian cancer treatment and survivorship.

Share

Ovarian Cancer News


Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer (November 9, 2016)

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed,... Continue Reading

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (October 31, 2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy.... Continue Reading

Tesaro Provides Real Benefit to Ovarian Cancer Patients (October 20, 2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase... Continue Reading

FDA Warns Against Ovarian Cancer Screening Tests (October 6, 2016)

According to the US Food and Drug Administration (FDA) doctors and their patients should not use certain ovarian cancer screening tests because of inaccurate results. Screening tests are designed to detect... Continue Reading

National Ovarian Cancer Coalition Launches CancerConnect Social Media Platform for Women with Ovarian Cancer (September 26, 2016)

Austin TX/Sun Valley ID–The National Ovarian Cancer Coalition (NOCC) now offers a specialized social network for women with ovarian cancer. The NOCC CancerConnect Community offers these women a safe,... Continue Reading

Pass it On: It’s National Ovarian Cancer Awareness Month (September 15, 2016)

In 2016, the American Cancer Association estimates that 22,280 women will be diagnosed with ovarian cancer, and 14,240 women will die from the disease. The incidence of ovarian cancer has decreased slightly... Continue Reading

Faces of Hope: Ovarian Cancer Advocates Speak Out (September 8, 2016)

Ovarian cancer survivors share their stories to provide inspiration and en­courage awareness of early detection. For many years ovarian cancer has been referred to as “the silent killer” due to its... Continue Reading

FDA Accepts Priority Review of Rucaparib For The Treatment Of Advanced Mutant BRCA Ovarian Cancer (September 6, 2016)

The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application for the treatment of advanced... Continue Reading

SGO, ASCO Issue New Guidelines for Ovarian Cancer Treatment (August 22, 2016)

A new joint clinical practice guideline from the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO) states that neoadjuvant chemotherapy (NACT) is the optimal first-line... Continue Reading

T-Cells Can be Directed to Treat a Variety of Ovarian Cancers (August 11, 2016)

With only incremental improvements in ovarian cancer survival over the last 40 years, there is a clear need for new treatment options with long-lasting results. Many researchers have turned toward the... Continue Reading

More Ovarian Cancer News

Latest Ovarian Cancer News By Stage


Screening and Prevention

FDA Warns Against Ovarian Cancer Screening Tests (October 6, 2016)

According to the US Food and Drug Administration (FDA) doctors and their patients should not use certain ovarian cancer screening tests because of inaccurate results. Screening tests are designed to detect cancer in its earliest stages when it is most... Continue Reading

National Ovarian Cancer Coalition Launches CancerConnect Social Media Platform for Women with Ovarian Cancer (September 26, 2016)

Austin TX/Sun Valley ID–The National Ovarian Cancer Coalition (NOCC) now offers a specialized social network for women with ovarian cancer. The NOCC CancerConnect Community offers these women a safe, secure, and private online resource, where they can... Continue Reading

Pass it On: It’s National Ovarian Cancer Awareness Month (September 15, 2016)

In 2016, the American Cancer Association estimates that 22,280 women will be diagnosed with ovarian cancer, and 14,240 women will die from the disease. The incidence of ovarian cancer has decreased slightly in the past decade or so, though the reason... Continue Reading

Ask the Lynch Syndrome Expert Q&A Now Available (June 2, 2016)

CancerConnect Presents: Ask the Expert with Dana-Farber Cancer Institute’s Dr. Perez* CancerConnect recently collaborated with the Dana-Farber Cancer Institute to provide you with the opportunity to engage with a hereditary cancers expert, Kimberly... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced... Continue Reading

More Screening and Prevention

Stage I

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (October 31, 2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for... Continue Reading

National Ovarian Cancer Coalition Launches CancerConnect Social Media Platform for Women with Ovarian Cancer (September 26, 2016)

Austin TX/Sun Valley ID–The National Ovarian Cancer Coalition (NOCC) now offers a specialized social network for women with ovarian cancer. The NOCC CancerConnect Community offers these women a safe, secure, and private online resource, where they can... Continue Reading

Pass it On: It’s National Ovarian Cancer Awareness Month (September 15, 2016)

In 2016, the American Cancer Association estimates that 22,280 women will be diagnosed with ovarian cancer, and 14,240 women will die from the disease. The incidence of ovarian cancer has decreased slightly in the past decade or so, though the reason... Continue Reading

Intraperitoneal Chemotherapy Underused in Ovarian Cancer (September 28, 2015)

The use of intraperitoneal (IP) chemotherapy appears to be utilized in fewer than 50% of clinical practices, despite results indicating improved survival with its use in certain patients with ovarian cancer. These results were recently published in the... Continue Reading

Ovarian Cancer Awareness: Risk, Prevention, Treatment, Survivorship, & Community (September 2, 2015)

As the month of September brings ovarian cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated ovarian cancer... Continue Reading

More Stage I

Stages II-IV

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer (November 9, 2016)

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.1 Results from... Continue Reading

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (October 31, 2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for... Continue Reading

Tesaro Provides Real Benefit to Ovarian Cancer Patients (October 20, 2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase (PARP) inhibitor with chemotherapy. Tesaro... Continue Reading

National Ovarian Cancer Coalition Launches CancerConnect Social Media Platform for Women with Ovarian Cancer (September 26, 2016)

Austin TX/Sun Valley ID–The National Ovarian Cancer Coalition (NOCC) now offers a specialized social network for women with ovarian cancer. The NOCC CancerConnect Community offers these women a safe, secure, and private online resource, where they can... Continue Reading

Pass it On: It’s National Ovarian Cancer Awareness Month (September 15, 2016)

In 2016, the American Cancer Association estimates that 22,280 women will be diagnosed with ovarian cancer, and 14,240 women will die from the disease. The incidence of ovarian cancer has decreased slightly in the past decade or so, though the reason... Continue Reading

More Stages II-IV

Recurrent

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer (November 9, 2016)

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.1 Results from... Continue Reading

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (October 31, 2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for... Continue Reading

Tesaro Provides Real Benefit to Ovarian Cancer Patients (October 20, 2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase (PARP) inhibitor with chemotherapy. Tesaro... Continue Reading

National Ovarian Cancer Coalition Launches CancerConnect Social Media Platform for Women with Ovarian Cancer (September 26, 2016)

Austin TX/Sun Valley ID–The National Ovarian Cancer Coalition (NOCC) now offers a specialized social network for women with ovarian cancer. The NOCC CancerConnect Community offers these women a safe, secure, and private online resource, where they can... Continue Reading

Niraparib Improves Progression-Free Survival in Ovarian Cancer (July 13, 2016)

The PARP inhibitor niraparib improves the time to cancer progression among patients with recurrent ovarian cancer when used as maintenance therapy during platinum-based chemotherapy. Each year in the United States, approximately 22,000 women are diagnosed... Continue Reading

More Recurrent

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS